Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg nudges up target price on Greggs

(Sharecast News) - Analysts at Berenberg slightly raised their target price on bakery chain Greggs from 3,040.00p to 3,060.00p on Wednesday, noting that the group's "fresh strategy announcements add flavour". Greggs reported positive strategic progression on Tuesday, in Berenberg's view, noting that while like-for-like and total revenues were pre-reported in an update earlier in July, profitability outcomes had not been. Management reported group adjusted pre-tax profits of £63.5m, which reflected a 3% beat versus consensus estimates.

Despite this, Berenberg noted that Greggs' shares traded roughly 5% lower on insignificant trading news, leading to a further deterioration in what it said was a share price that already reflected "subdued sentiment".

"We continue to think that the fundamentals of the equity story are detached from the current valuation multiple, which seems to infer imminent store estate saturation without sufficient cause, in our view," said the German bank. "We have made insignificant changes to our earnings forecasts. We have increased our FY 2026E adjusted operating profit expectation marginally, to reflect the reversion of the hot weather impact to June 2025, and have tweaked our net interest and tax charge forecasts to reflect H1 outcomes and guidance commentary."

Berenberg, which reiterated its 'buy' rating on the stock, added that Greggs currently trades on a 12.5x 12-month forward price-to-earnings ratio, more than one standard deviation below its trailing three-year historical average.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.